Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs.
Mebendazole is practically insoluble in water and studies of its polymorphism has led to the identification and characterization of three polymorphic forms (A, B, C) displaying solubility and therapeutic differences that show that polymorph C is therapeutically favored. The objective of this study was to adjust the USP dissolution test for mebendazole so that it was able to distinguish between the dissolution properties of three mebendazole polymorphs. This would provide generic manufacturers with one more test to ensure that the therapeutically active polymorph C is used. The results obtained in this study show that the USP dissolution test conditions were not able to distinguish between the dissolution properties of completely dispersed mebendazole polymorphs with comparable particle sizes. When sodium lauryl sulfate was removed from the dissolution medium, the percentage dissolved versus time profiles changed so that polymorph C dissolved faster (70% within 120 min) compared to polymorph B (37% within 120 min) and polymorph A (20% within 120 min).
Swanepoel
Erna
E
Research Institute for Industrial Pharmacy, Potchefstroom University for CHE, Potchefstroom, South Africa.
Liebenberg
Wilna
W
de Villiers
Melgardt M
MM
D002626:Chemistry, Pharmaceutical; D004353:Drug Evaluation, Preclinical / Q000379:methods; D016568:Drugs, Generic / Q000737:chemistry* / Q000592:standards*; D008463:Mebendazole / Q000737:chemistry* / Q000592:standards*; D012995:Solubility
D016568:Drugs, Generic; D008463:Mebendazole